Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials

doi:10.1016/S1473-3099(05)70218-8

The Lancet Infectious Diseases

Volume 5, Issue 9, September 2005, Pages 581-589

https://doi.org/10.1016/S1473-3099(05)70218-8 Get rights and content

Summary

Intermittent intravenous administration of antibiotics is the first-line approach in the management of severe infections worldwide. However, the potential benefits of alternate modes of administration of antibiotics, including continuous intravenous infusion, deserve further evaluation. We did a meta-analysis of randomised controlled trials comparing continuous intravenous infusion with intermittent intravenous administration of the same antibiotic regimen. Nine randomised controlled trials studying beta-lactams, aminoglycosides, and vancomycin were included. Clinical failure was lower, although without statistical significance, in patients receiving continuous infusion of antibiotics (pooled OR 0·73, 95% CI 0·53–1·01); the difference was statistically significant in a subset of randomised controlled trials that used the same total daily antibiotic dose for both intervention arms (0·70, 0·50–0·98, fixed and random effects models). Regarding mortality and nephrotoxicity, no differences were found (mortality 0·89, 0·48–1·64; nephrotoxicity 0·91, 0·56–1·47). In conclusion, the data suggest that the administration of the same total antibiotic dose by continuous intravenous infusion may be more efficient, with regard to clinical effectiveness, compared with the intermittent mode. In an era of gradually increasing resistance among most pathogens, the potential advantages of continuous intravenous administration of antibiotics on several clinical outcomes should be further investigated.

Introduction

Although intermittent intravenous administration of antibiotics is the standard clinical practice worldwide, there is renewed interest among clinicians and researchers in examining the benefits of continuous administration of antibiotics, since there is potential for further improvement of the outcome of patients treated with antibiotics for severe infections in most clinical settings. In addition, there are limitations in the development and introduction of new antibiotics into clinical practice. Therefore, the optimisation of the therapeutic potential of currently available antibiotics has become a necessity for the management of severe infections caused by multidrug-resistant bacteria.

There are several clinical studies comparing the effectiveness and toxicity of continuous versus intermittent intravenous administration of antibiotics, with conflicting results.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 Moreover, the interpretation of their results remains controversial, because most of the trials were done with relatively small numbers of patients. We did a meta-analysis of randomised clinical trials that compared continuous intravenous administration with intermittent intravenous administration of antimicrobial agents to evaluate their effectiveness and toxicity.

Section snippets

Data sources

Relevant studies for our meta-analysis were identified from PubMed (Jan 1950–Sep 2004), Current Contents, the Cochrane central register of controlled trials, and references from relevant articles and review papers. Search terms included “continuous”, “intravenous”, “antibiotics”, “intermittent”, “bolus”, “dosing”, “infusion”, “discontinuous”, and “administration”. Abstracts presented in international conferences were not searched.

Study selection

Two independent reviewers did literature searches and examined

Trial characteristics

Our literature search strategy identified 74 clinical or pharmacokinetic/pharmacodynamic studies regarding continuous intravenous infusion of antimicrobial agents.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78 46 of 74 studies were comparative studies and were

Discussion

To our knowledge, this study is the first meta-analysis of randomised controlled trials that compared outcomes of patients receiving continuous versus intermittent intravenous antibiotics. Our study, including 20 comparisons from nine randomised controlled trials, showed that clinical failure was lower, although without statistical significance, in patients receiving continuous infusion of antibiotics; the difference was statistically significant in a subset of randomised controlled trials that

Search strategy and selection criteria

This information is described in detail in the data sources section.

References (85)

GP Bodey et al.
A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients
Am J Med
(1979)
GP Giacoia et al.
Pharmacokinetics and nephrotoxicity of continuous intravenous infusion of gentamicin in low birth weight infants
J Pediatr
(1986)
SD Hanes et al.
Intermittent and continuous ceftazidime infusion for critically ill trauma patients
Am J Surg
(2000)
DP Nicolau et al.
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia
Int J Antimicrob Agents
(2001)
AR Jadad et al.
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
Control Clin Trials
(1996)
R DerSimonian et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986)
DS Burgess et al.
Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion
Clin Ther
(2000)
DS Burgess et al.
Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing
Clin Ther
(2002)
DS Burgess et al.
Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion
Clin Ther
(1999)
GG Chabot et al.
Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients
J Pharm Sci
(1989)

G Egerer et al.

Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation

Int J Antimicrob Agents

(2000)

JL Kuti et al.

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis

Clin Ther

(2004)

D Andes et al.

Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy

Infect Dis Clin North Am

(1998)

AS Benko et al.

Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections

Antimicrob Agents Chemother

(1996)

JA Bosso et al.

A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis

Pharmacotherapy

(1999)

A Di Filippo et al.

Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection

Chemotherapy

(1998)

R Feld et al.

Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole

Arch Intern Med

(1984)

B Georges et al.

Continuous versus intermittent cefepime infusion in critical care. Preliminary results

Pathol Biol (Paris)

(1999)

JK James et al.

Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections

Antimicrob Agents Chemother

(1996)

S Jaruratanasirikul et al.

Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia

J Pharm Pharmacol

(2002)

H Lagast et al.

Treatment of gram-negative bacillary septicemia with cefoperazone

Eur J Clin Microbiol

(1983)

M Wysocki et al.

Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study

Antimicrob Agents Chemother

(2001)

M Egger et al.

Bias in meta-analysis detected by a simple, graphical test

BMJ

(1997)

N Mantel et al.

Statistical aspects of the analysis of data from retrospective studies of disease

J Natl Cancer Inst

(1959)

BJ Angus et al.

Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis

Br J Clin Pharmacol

(2000)

KQ Bui et al.

Pharmacokinetics and pharmacoeconomic evaluation of ticarcillin-clavulanate administered as either continuous or intermittent infusion with once-daily gentamycin

Infect Dis Clin Pract

(1999)

SL Buijk et al.

Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections

J Antimicrob Chemother

(2002)

B Byl et al.

Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion

Antimicrob Agents Chemother

(2003)

H Eagle et al.

“Continuous” vs. “discontinuous” therapy with penicillin; the effect of the interval between injections on therapeutic efficacy

N Engl J Med

(1953)

U Eriksson et al.

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

BMJ

(2001)

R Feld et al.

A comparative trial of sisomicin therapy by intermittent versus continuous infusion

Am J Med Sci

(1977)

NR Florea et al.

Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study

Am J Health Syst Pharm

(2003)

EM Grant et al.

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital

Pharmacotherapy

(2002)

CM Hitt et al.

Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime

Am J Health Syst Pharm

(1997)

U Hollenstein et al.

Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers

Clin Pharmacol Ther

(2000)

ME Klepser et al.

Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis

Pharmacotherapy

(1998)

K Leder et al.

The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis

J Antimicrob Chemother

(1999)

SW Lemmen et al.

Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 h versus intermittent bolus infusion of 2 g against Pseudomonas aeruginosa in healthy volunteers

J Antimicrob Chemother

(1997)

J Lipman et al.

Continuous infusion ceftazidime in intensive care: a randomized controlled trial

J Antimicrob Chemother

(1999)

C Martin et al.

Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery

Antimicrob Agents Chemother

(1998)

JJ McNabb et al.

Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia

Pharmacotherapy

(2001)

JW Mouton et al.

Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers

Antimicrob Agents Chemother

(1990)

Cited by (163)

Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: A narrative review
2024, Journal of Intensive Medicine
Effective treatment of sepsis not only demands prompt administration of appropriate antimicrobials but also requires precise dosing to enhance the likelihood of patient survival. Adequate dosing refers to the administration of doses that yield therapeutic drug concentrations at the infection site. This ensures a favorable clinical and microbiological response while avoiding antibiotic-related toxicity. Therapeutic drug monitoring (TDM) is the recommended approach for attaining these goals. However, TDM is not universally available in all intensive care units (ICUs) and for all antimicrobial agents. In the absence of TDM, healthcare practitioners need to rely on several factors to make informed dosing decisions. These include the patient's clinical condition, causative pathogen, impact of organ dysfunction (requiring extracorporeal therapies), and physicochemical properties of the antimicrobials. In this context, the pharmacokinetics of antimicrobials vary considerably between different critically ill patients and within the same patient over the course of ICU stay. This variability underscores the need for individualized dosing. This review aimed to describe the main pathophysiological changes observed in critically ill patients and their impact on antimicrobial drug dosing decisions. It also aimed to provide essential practical recommendations that may aid clinicians in optimizing antimicrobial therapy among critically ill patients.
Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function
2023, Respiratory Medicine
Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy have resulted in longer life expectancies, yet pulmonary exacerbations remain a leading cause of morbidity. Intravenous antibiotics is the mainstay treatment, however achieving adequate concentrations remains challenging. The effect of therapeutic drug monitoring (TDM) of beta-lactams on exacerbations and lung function has not been studied.
Patient demographics, antibiotic regimens, forced expiratory volume 1 s (FEV1), and exacerbation history was obtained from 32 patients with cystic fibrosis admitted for exacerbations. All patients were colonized with Pseudomonas aeruginosa, received CFTR therapy for at least one year, and had 3-month interval follow ups. Plasma concentrations, FEV1, and exacerbation history was obtained before and after therapeutic drug monitoring. This included peak and trough plasma concentrations of piperacillin-tazobactam and cefepime using liquid chromatography with mass spectrometry. T-test and Mann-Whitney U test were used to compare medians/means of FEV1 and pulmonary exacerbations pre and post-TDM as well as free trough-to-minimum inhibitory concentration ratio (fC_min/MIC) ≥1 and ≥ 4.
TDM was associated with decreased exacerbations/year from 1.91 to 1.31 (p = 0.04) and among the cohort with >/ = 2 exacerbations per year, there was a longer exacerbation free interval after TDM (196.2 vs 103.7 days, p = 0.02). The decline in FEV1% predicted after therapeutic drug monitoring to the first exacerbation was −4.9 compared to −9.7 prior (p = 0.03).
TDM for cystic fibrosis pulmonary exacerbations results in decreased pulmonary exacerbations, longer intervals to pulmonary exacerbation, and lower decline in FEV1% predicted.
Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics in critically ill patients
2022, Farmacia Hospitalaria
Optimal antibiotic therapy for critically ill patients can be complicated by the altered physiology associated with critical illness. Antibiotic pharmacokinetics and exposures can be altered driven by the underlying critical illness and medical interventions that critically ill patients receive in the intensive care unit. Furthermore, pathogens that are usually isolated in the intensive care unit are commonly less susceptible and “resistant” to common antibiotics. Indeed, antibiotic dosing that does not consider these unique differences will likely fail leading to poor clinical outcomes and the emergence of antibiotic resistance in the intensive care unit. The aims of this narrative review were to describe the pharmacokinetics of beta-lactam antibiotics in critically ill patients, to highlight pharmacokinetic/pharmacodynamic targets for both non-critically ill and critically ill patients, and to discuss important strategies that can be undertaken to optimize beta-lactam antibiotic dosing for critically ill patients in the intensive care unit.
La terapia antibiótica óptima en los pacientes en estado crítico puede complicarse por la alteración de la fisiología asociada a esta etapa de la enfermedad. La farmacocinética y la exposición a los antibióticos pueden verse alteradas por la enfermedad crítica subyacente y las intervenciones médicas que reciben estos pacientes en la unidad de cuidados intensivos. Además, las cepas que suelen encontrarse en la unidad de cuidados intensivos suelen ser menos susceptibles y “resistentes” a los antibióticos más habituales. De hecho, una dosificación de antibióticos que no tenga en cuenta estas diferencias únicas, probablemente fracasará y dará lugar a resultados clínicos deficientes y a la aparición de resistencia a los antibióticos en la unidad de cuidados intensivos. Los objetivos de esta revisión son describir la farmacocinética de los antibióticos betalactámicos en pacientes críticos, destacar los objetivos farmacocinéticos/farmacodinámicos para los pacientes y exponer algunas estrategias importantes que pueden optimizar la dosificación de los antibióticos betalactámicos en pacientes críticos en la unidad de cuidados intensivos.
Are β-lactam concentrations adequate in severe sepsis and septic shock in children?
2020, Therapies
Early administration of appropriate antibiotic therapy with adequate concentration is the cornerstone of the severe sepsis and septic shock's treatment. We aim to describe the plasma concentration of the most used β-lactams in critically ill children, to describe the rate of patients with suboptimal exposure, and associated clinical and biological factors.
From January 2016 to May 2017, children less than 18 years old with severe sepsis or septic shock were included. Samples were collected in pediatric intensive care unit for children with severe sepsis or septic shock. β-lactam plasma concentrations were analysed using high performance liquid chromatography.
Among the 37 enrolled patients, 24 (64.9%) had insufficient concentration [cefotaxime 7/14 (43%); piperacillin–tazobactam, 10/13 (77%); amoxicillin 6/7 (86%); meropenem 3/6 (50%), cefazolin 1/4 (25%), imipenem 0/2 (0%); ceftazidime 0/1 (0%)]. Insufficient concentrations were associated with early measurements [<72 hours from the sepsis’ onset (P = 0.035) and an increased creatinine clearance (P = 0.01)].
β-lactams current dosing in critically ill septic children could be suboptimal.
Should doses of antibiotics be adjusted?
2018, Revue de Medecine Interne
Alors que l’on est confronté à l’accroissement majeur de la résistance aux antibiotiques, la préservation des antibiotiques existants qui passe par l’optimisation de leur utilisation, tant pour obtenir le succès thérapeutique que pour limiter les risques d’émergence de la résistance, est un enjeu majeur. L’optimisation de l’utilisation des antibiotiques impose une adaptation des posologies qui doit répondre à un triple objectif : garantir l’efficacité antibactérienne, limiter les toxicités et l’émergence de souches résistantes au niveau du site infectieux. Or, avec l’accroissement du nombre de patients multipathologiques, atteints notamment d’insuffisance rénale ou hépatique, l’augmentation du nombre de patients au poids extrêmes et l’utilisation d’antibiotiques aux marges thérapeutiques plus étroites en raison de la résistance, l’adaptation des posologies d’antibiotiques prend une importance croissante. En rappelant quelques principes de pharmacocinétique et de pharmacodynamie (PK/PD), nous rappelons par classe d’antibiotiques les objectifs nécessaires à l’efficacité clinique, avant de citer des exemples de situations où les adaptations posologiques sont nécessaires, notamment chez les patients obèses. Cette attitude ne se limite pas seulement à l’adaptation de la posologie journalière totale. Les paramètres PK/PD nous apprennent en effet aussi que le mode d’administration (intermittent ou continu, nombre d’injections par jour, etc.) est également un point essentiel à prendre en compte. À partir d’exemples concernant certaines molécules, certaines infections et certaines situations cliniques difficiles, nous décrivons les situations où les adaptations posologiques semblent nécessaires.
While we are confronted with the major increase in antibiotic resistance, the preservation of existing antibiotics has become an absolute necessity both to achieve therapeutic success and to limit the risks of the emergence of resistance. The optimization of antibiotic use and dosages must have a threefold objective: guarantee antibacterial efficacy, limit toxicities and limit emergence of resistant strains. However, with the increase in the number of multipathological patients, particularly those with renal or hepatic impairment, the increase in the number of patients with extreme weights and the use of antibiotics with narrower therapeutic margins, the adaptation of antibiotic dosages is becoming increasingly important. By reminding some principles of pharmacokinetics and pharmacodynamics of antibiotics (PK/PD), the necessary objectives for clinical effectiveness of most antibiotic classes are reviewed and several examples of situations where dosage adjustments are necessary will be given. In particular, adjustment of antibiotic dosages in obese patients will be discussed. Adaptation is not limited to the adaptation of the total daily dose. The PK/PD parameters also tell us that the mode of administration (intermittent versus continuous, number of injections per day, etc.) is also an essential point to consider. By taking examples concerning some molecules, infections and difficult clinical situations, we review situations in which dosage adjustments appear necessary.
Antibiotic Dosing Considerations for Term and Preterm Infants
2018, Infectious Disease and Pharmacology: Neonatology Questions and Controversies
Early and appropriate antibiotic therapy can be lifesaving for severe infections in infants. However, physiologic differences in infants compared with older children and adults contribute to challenges in neonatal dosing. Neonatal-specific dosing regimens may be derived by pharmacokinetic modeling and simulation techniques. However, these techniques have resulted in disparate dosing recommendations for certain antibiotic therapies. Herein, we describe existing controversies for dosing-based measures of renal and hepatic growth, maturation, and function during the neonatal period. We detail existing data, risks, and benefits of alternate-interval dosing regimens in neonatal populations and provide considerations for adequate penetration of the blood–brain barrier and optimization of perioperative antibiotic management. Finally, we provide recommendations on dosing in critically ill infants supported with extracorporeal membrane oxygenation or receiving therapeutic hypothermia. Future studies should seek to identify the most appropriate measures of organ growth and maturation and establish appropriate antibiotic dosing recommendations to maximize bacterial killing and minimize toxicity.

View all citing articles on Scopus

View full text

ReviewContinuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials

Summary

Introduction

Section snippets

Data sources

Study selection

Trial characteristics

Discussion

Search strategy and selection criteria

Am J Med

J Pediatr

Am J Surg

Int J Antimicrob Agents

Control Clin Trials

Control Clin Trials

Clin Ther

Clin Ther

Clin Ther

J Pharm Sci

Int J Antimicrob Agents

Clin Ther

Infect Dis Clin North Am

Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections

Antimicrob Agents Chemother

A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis

Pharmacotherapy

Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection

Chemotherapy

Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole

Arch Intern Med

Continuous versus intermittent cefepime infusion in critical care. Preliminary results

Pathol Biol (Paris)

Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections

Antimicrob Agents Chemother

Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia

J Pharm Pharmacol

Treatment of gram-negative bacillary septicemia with cefoperazone

Eur J Clin Microbiol

Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study

Antimicrob Agents Chemother

Bias in meta-analysis detected by a simple, graphical test

BMJ

Statistical aspects of the analysis of data from retrospective studies of disease

J Natl Cancer Inst

Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis

Br J Clin Pharmacol

Pharmacokinetics and pharmacoeconomic evaluation of ticarcillin-clavulanate administered as either continuous or intermittent infusion with once-daily gentamycin

Infect Dis Clin Pract

Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections

J Antimicrob Chemother

Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion

Antimicrob Agents Chemother

“Continuous” vs. “discontinuous” therapy with penicillin; the effect of the interval between injections on therapeutic efficacy

N Engl J Med

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

BMJ

A comparative trial of sisomicin therapy by intermittent versus continuous infusion

Am J Med Sci

Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study

Am J Health Syst Pharm

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital

Pharmacotherapy

Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime

Am J Health Syst Pharm

Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers

Clin Pharmacol Ther

Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis

Pharmacotherapy

The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis

J Antimicrob Chemother

Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 h versus intermittent bolus infusion of 2 g against Pseudomonas aeruginosa in healthy volunteers

J Antimicrob Chemother

Continuous infusion ceftazidime in intensive care: a randomized controlled trial

J Antimicrob Chemother

Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery

Antimicrob Agents Chemother

Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia

Pharmacotherapy

Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers

Antimicrob Agents Chemother

Review
Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials